retatrutide test Triple receptor agonist studied for

Rhabdomyolysis has not been reported in clinical trials leading to the approval of tirzepatide

All available relevant studies were included

Interestingly, RYGB controls 5-HT 2A receptor availability in the ventral striatum in rats [112], suggesting that GLP-1R agonists and bariatric surgery may both target the midbrain serotonergic system to exert their inhibitory effects on energy balance

doi: 10.1038/s41598-021-00654-3 13 ShechterYTsuberyHMironchikMRubinsteinMFridkinM

TRIUMPH-4: Efficacy at 68 weeks TRIUMPH-4 (ClinicalTrials.gov identifier NCT05931367) enrolled 445 adults with obesity or overweight plus symptomatic knee osteoarthritis and no type 2 diabetes

[2] See, e.g ., FDA, Warning Letter to Expert Aesthetics (Sep